Trial Profile
Randomized Phase II Study of Atezolizumab (MPDL3280A) Plus Recombinant Human IL7 (CYT107) in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Mar 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Interleukin-7 (Primary)
- Indications Bladder cancer; Pelvic cancer; Renal cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
- Focus Therapeutic Use
- 27 Jan 2024 Results comparing the combination of CYT107/atezo to atezo alone in patients with metastatic urothelial carcinoma presented at the 2024 Genitourinary Cancers Symposium
- 24 Oct 2023 Results comparing the combination of CYT107 and atezo to atezo alone presented at the 48th European Society for Medical Oncology Congress
- 24 Oct 2023 Primary endpoint (Objective response rate (ORR)) has not been met according to result presented at the 48th European Society for Medical Oncology Congress.